Article date: March 2004
By: Ruth E Hannan, Tracey A Gaspari, Elizabeth A Davis, Robert E Widdop in Volume 141, Issue 6, pages 1024-1031
In the present study we determined whether angiotensin II (Ang II) could increase cyclic GMP levels in two blood vessels that exhibit markedly different angiotensin II receptor subtype expression: rat uterine artery (UA; AT2 receptor‐predominant) and aorta (AT1 receptor‐predominant), and investigated the receptor subtype(s) and intracellular pathways involved.
UA and aorta were treated with Ang II in the absence and presence of losartan (AT1 antagonist; 0.1 μM), PD 123319 (AT2 antagonist; 1 μM), NOLA (NOS inhibitor; 30 μM), and HOE 140 (B2 antagonist; 0.1 μM), or in combination.
Ang II (10 nM) induced a 60% increase in UA cyclic GMP content; an effect that was augmented with PD 123319 and HOE 140 pretreatment, and abolished by cotreatment with losartan, as well as by NOLA.
In aorta, Ang II produced concentration‐dependent increases in cyclic GMP levels. Unlike effects in UA, these responses were abolished by PD 123319 and by NOLA, whereas losartan and HOE 140 caused partial inhibition.
Thus, in rat UA, Ang II stimulates cyclic GMP production through AT1 and, to a less extent, AT2 receptors. In rat aorta, the Ang II‐mediated increase in cyclic GMP production is predominantly AT2 receptor‐mediated. In both preparations, NO plays a critical role in mediating the effect of Ang II, whereas bradykinin has differential roles in the two vessels. In UA, B2 receptor blockade may result in a compensatory increase in cyclic GMP production, whilst in aorta, bradykinin accounts for approximately half of the cyclic GMP produced in response to Ang II.
In the present study we determined whether angiotensin II (Ang II) could increase cyclic GMP levels in two blood vessels that exhibit markedly different angiotensin II receptor subtype expression: rat uterine artery (UA; AT2 receptor‐predominant) and aorta (AT1 receptor‐predominant), and investigated the receptor subtype(s) and intracellular pathways involved.
UA and aorta were treated with Ang II in the absence and presence of losartan (AT1 antagonist; 0.1 μM), PD 123319 (AT2 antagonist; 1 μM), NOLA (NOS inhibitor; 30 μM), and HOE 140 (B2 antagonist; 0.1 μM), or in combination.
Ang II (10 nM) induced a 60% increase in UA cyclic GMP content; an effect that was augmented with PD 123319 and HOE 140 pretreatment, and abolished by cotreatment with losartan, as well as by NOLA.
In aorta, Ang II produced concentration‐dependent increases in cyclic GMP levels. Unlike effects in UA, these responses were abolished by PD 123319 and by NOLA, whereas losartan and HOE 140 caused partial inhibition.
Thus, in rat UA, Ang II stimulates cyclic GMP production through AT1 and, to a less extent, AT2 receptors. In rat aorta, the Ang II‐mediated increase in cyclic GMP production is predominantly AT2 receptor‐mediated. In both preparations, NO plays a critical role in mediating the effect of Ang II, whereas bradykinin has differential roles in the two vessels. In UA, B2 receptor blockade may result in a compensatory increase in cyclic GMP production, whilst in aorta, bradykinin accounts for approximately half of the cyclic GMP produced in response to Ang II.
British Journal of Pharmacology (2004) 141, 1024–1031. doi:10.1038/sj.bjp.0705694
DOI: 10.1038/sj.bjp.0705694
View this article